

# Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients

## Authors

Suheil Albert Atallah-Yunes,<sup>1</sup> Matthew J. Rees,<sup>1</sup> Thomas M. Habermann,<sup>1</sup> Yucai Wang,<sup>1</sup> Javier Munoz,<sup>2</sup> Madiha Iqbal,<sup>3</sup> Jose C. Villasboas,<sup>1</sup> Ellen D. McPhail,<sup>4</sup> Thomas E. Witzig,<sup>1</sup> Stephen M. Ansell<sup>1</sup> and Grzegorz S. Nowakowski<sup>1</sup>

<sup>1</sup>Division of Hematology, Mayo Clinic, Rochester, MN; <sup>2</sup>Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ;

<sup>3</sup>Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL and <sup>4</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Correspondence:

S. A. ATALLAH-YUNES - Albert.atallahmd@gmail.com,  
Atallah-Yunes.SuheilAbert@mayo.edu

<https://doi.org/10.3324/haematol.2025.288145>

Received: April 28, 2025.

Accepted: June 11, 2025.

Early view: June 19, 2025.


©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



## SUPPLEMENT

**Supplementary Figure 1.** Treatment approaches and outcomes among 66 patients with colorectal MALT lymphoma stage I-IIIE.



NA, not applicable; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; EFS, event free survival.

\* n=2 patients received rituximab consolidation following endoscopic resection, n=2 patients received adjuvant radiation following endoscopic resection

<sup>^</sup>n=1 lymphoma related death and caused by transformation to diffuse large B cell lymphoma

#n=1 patient received bendamustine + rituximab when progressed after initial observation

+chemoimmunotherapy regimens: cyclophosphamide, vincristine and prednisone (CVP), yttrium-90 ibritumomab tiuxetan and chlorambucil.